8 07, 2018

Argentina: Stockouts of ARVs threatens continuation of HIV treatments

2020-08-04T16:58:43-03:00domingo, 8 julio, 2018|Producciones en inglés|

Buenos Aires, July 6 2018.  In a context of economic crisis of magnitude that Argentina is facing there are stockouts of essential medicines. According to key informants, the shortage of medicines is due to the lack of public purchases. While the authorities of the Ministry of Health delay the provision of official information there are disruptions

4 12, 2017

Hepatitis C: In Argentina INPI rejected a key patent on Sofosbuvir

2020-08-04T17:02:32-03:00lunes, 4 diciembre, 2017|Producciones en inglés|

Argentina has made an important step forward to protect  local production of generics of an essential medicine to treat Hepatitis C. This brings significant advantages for Public Programs which procure the medicines. Por: Julia Varela Buenos Aires, December 4, 2017. In Argentina, the INPI (National Institute of Industrial Property) rejected GILEAD PHARMASSET LLC patent application

24 05, 2017

Gilead forced to withdraw Truvada® patent application in Argentina

2020-08-04T17:14:34-03:00miércoles, 24 mayo, 2017|Producciones en inglés|

The decision, for which the Fundación GEP contributed with/to decisive arguments, paves the way to generic versions to facilitate access to treatments. Por: Julia Varela May 23, 2017 - In a resolution that means a step forward in safeguarding the right to health, Argentina’s patent office (the National Institute of Industrial Property - INPI) forced

29 03, 2017

Argentina’s Patent Office signs bilateral agreement with the US harming public health and national laws

2017-03-29T20:16:15-03:00miércoles, 29 marzo, 2017|Access to Medicines, Argentina, Health Safeguards, Intellectual Property, Public Health|

The Argentinian National Institute of Industrial Property (INPI, by its acronym in Spanish) signed a bilateral agreement with the US Patent Office on February 13th that includes reciprocal acceptance of patenting results of both offices. The news are grave and serious as the "Patent Prosecution Highway Between USPTO and INPI-Argentina" effectively repeals the Argentine Patent

14 02, 2017

GEP filed new opposition to patent request for Hepatitis C drug in Argentina

2020-08-04T17:19:32-03:00martes, 14 febrero, 2017|Producciones en inglés|

Por: Julia Varela BUENOS AIRES, February 14, 2017 - The GEP Foundation and Intiative for Medicines, Access and Knowledge (IMAK) filed yesterday an opposition at the National Institute of Industrial Property (INPI) to the patent request by multinational pharmaceutical company Gilead on the base compound of sofosbuvir, a drug that represents the cure for hepatitis C. The action means a great step to

14 11, 2016

International Congress on Access to Medicines, Medical Technologies and Human Rights

2020-08-04T17:23:25-03:00lunes, 14 noviembre, 2016|Producciones en inglés|

Buenos Aires, Argentina – 16, 17 and 18 November 2016 15 years of the Doha Declaration on TRIPS and Public Health: Health Safeguards as effective tools to protect Health and exercise Sanitary Sovereignty. Fundación GEP invites to the International Congress on Access to Medicines, Medical Technologies and Human Rights that will take place in Buenos Aires, Argentina. The

15 09, 2016

Big Pharma’s court cases in Brazil & Argentina threaten national laws considered important public health safeguards in the UN HLP report

2020-08-04T17:29:58-03:00jueves, 15 septiembre, 2016|Producciones en inglés|

September 15th 2016 - Press release Fundación Grupo Efecto Positivo (FGEP) - Associação Brasileira Interdisciplinar de AIDS (ABIA) - Grupo de Trabalho sobre Propriedade Intelectual (GTPI) United Nations’ High Level Panel on Access to Medicines Report released: Big Pharma’s court cases in Brazil & Argentina threaten to dismantle the national laws considered as important public health safeguards

17 12, 2015

FGEP continues defense of public health in Argentina against the abuse of the patent system by multinational pharmaceutical companies

2015-12-17T03:50:58-03:00jueves, 17 diciembre, 2015|Access to Medicines, Argentina, Direct Action, Health Safeguards, HIV, Intellectual Property, Kaletra, Patent opposition, Sofosbuvir|

BUENOS AIRES, December 15th 2015 - Fundación Grupo Efecto Positivo (FGEP), an organization whose work is focused on guaranteeing access to essential medicines for HIV and Hepatitis C in Argentina and Latin America, announced in a press conference on November 30th two new key actions to defend public health policies. Dr. Daniel Gollán, Argentina’s Minister

4 11, 2015

Argentina could save U$11M per year buying generic version of Truvada®

2015-11-04T20:01:06-03:00miércoles, 4 noviembre, 2015|Access to Medicines, Advocacy, Health Safeguards, Intellectual Property, Patent opposition|

The Argentine Community of People Living with HIV requested the rejection of a patent for an essential HIV/AIDS medicine. If the Argentine Patent Office does grant the this request, Argentina could produce generic versions at a lower cost representing a potential saving of over US$11 million. Argentina April 13th, 2015.- The Grupo Efecto Positivo Foundation (FGEP) in collaboration with the Argentine

Ir a Arriba